O. Reg. 498/17: REPORTS
filed December 15, 2017 under Health Protection and Promotion Act, R.S.O. 1990, c. H.7
Skip to contentontario regulation 498/17
made under the
Health Protection and Promotion Act
Made: December 13, 2017
Filed: December 15, 2017
Published on e-Laws: December 15, 2017
Printed in The Ontario Gazette: December 30, 2017
Amending Reg. 569 of R.R.O. 1990
(REPORTS)
1. Paragraph 1 of subsection 1 (1) of Regulation 569 of the Revised Regulations of Ontario, 1990 is revoked and the following substituted:
1. Name and address in full and, if available, any other contact information.
2. Section 3 of the Regulation is revoked and the following substituted:
3. (1) A report made under subsection 29 (1) of the Act shall, with respect to the person to whom the finding was made, be made within 24 hours of the making of the finding and shall contain the following information:
1. Name and address in full.
2. Date of birth in full.
3. Sex.
4. Date when the specimen was taken that yielded the positive finding.
5. Name and address in full of the physician, registered nurse in the extended class, dentist or other health care provider as indicated on the most recent test requisition.
(2) A report made under subsection 29 (1) of the Act shall contain the following information with respect to a person to whom a finding of Hepatitis C was made, if available, in addition to the information required under subsection (1) of this section:
1. Results of Hepatitis C serologic tests from the time of the first positive confirmed Hepatitis C serologic test, back to, and including, the most recent negative result.
2. Results of all Hepatitis C RNA tests including any initial tests and any tests done at any time subsequent to the initial test.
3. The date of specimen collection and the date the final test result was reported.
3. Subsection 3.1 (2) of the Regulation is amended by adding the following paragraph:
6. Any additional information that the medical officer of health considers necessary from the reporting laboratory respecting the reportable or communicable disease.
4. (1) Subparagraphs 1 x, xi and xii of section 5 of the Regulation are revoked and the following substituted:
x. Contacts.
xi. Risk factors.
(2) Subparagraphs 2 v and vi of section 5 of the Regulation are revoked and the following substituted:
v. Contacts.
(3) Subparagraph 2 xiii of section 5 of the Regulation is revoked and the following substituted:
xiii. Travel history, both within and outside Canada.
(4) Subparagraphs 3 viii, ix, x, xi and xii of section 5 of the Regulation are revoked and the following substituted:
viii. Risk factors.
(5) Subparagraphs 4 iv, v, vi and vii of section 5 of the Regulation are revoked and the following substituted:
iv. Travel history, both within and outside Canada.
v. Exposure to any of the following (Give date and time along with details relating to personal protective equipment used, if any):
A. Known reservoir of the pathogen (for example, bats, rodents, monkeys).
B. Persons with a similar illness.
C. Virus in a laboratory.
vi. Clinical history:
A. Date of onset of illness.
B. Symptoms and signs of the illness.
C. Rule out other causes of febrile illness, including, without being limited to, malaria.
(6) Paragraph 5 of section 5 of the Regulation is revoked and the following substituted:
5. Acute Flaccid Paralysis, Chickenpox (Varicella), Diphtheria, Haemophilus influenzae b disease, invasive, Measles, Meningococcal disease, invasive, Mumps, Pertussis (Whooping Cough), Pneumococcal disease, invasive, Poliomyelitis, acute, Rubella, Rubella, congenital syndrome, Tetanus:
i. The date of the diagnosis.
ii. The agent of disease.
iii. The name and address of the physician or registered nurse in the extended class attending the person.
iv. Medical condition and status of the person, including signs, symptoms and site, if any, of the infection.
v. The clinical history of the person, including:
A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital, or the name of the hospital if the person is seen as an out-patient of the hospital.
B. The date and duration of isolation, if isolated.
C. Full vaccination history pertaining to the disease in question, including type of vaccine or vaccines and date or dates of receipt.
vi. The case classification of the person.
vii. Laboratory findings and other investigative tests including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.
viii. Association with outbreak and outbreak number, if applicable.
ix. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.
x. Completion of the course of treatment, including the major mode of therapy and the treatment compliance.
xi. Place where infection is believed to have been acquired.
xii. The source of infection, including history of exposures and potential for community transmission.
xiii. Risk factors.
xiv. The immigration status and origin of the person, including:
A. Country of birth.
B. Country of last residence.
C. Date of arrival in Canada.
D. Immigration status at time of arrival in Canada.
xv. Travel history, both within and outside Canada.
xvi. The employment details of the person, including job title and place of employment.
xvii. The name and address of the school the person attends, if applicable, including the classroom.
xviii. Contacts.
xix. Number of contacts traced (excluding Tetanus, Pneumococcal disease, invasive and Acute Flaccid Paralysis).
xx. Outcome:
A. If the person is deceased, date and cause of death.
B. Complications.
C. Absconded — lost to follow-up before treatment completion.
D. Other.
(7) Subparagraphs 6 x to xxv of section 5 of the Regulation are revoked and the following substituted:
x. Risk factors.
xi. The immigration status and origin of the person, including:
A. Country of birth.
B. Country of last residence.
C. Date of arrival in Canada.
D. Unique Client Identifier number (“UCI#”) or Immigration Medical Examination number (“IME#”) if UCI# is unknown.
E. Date reported for medical surveillance (has made contact with, or been contacted by, the health unit, if applicable).
F. Date clinically assessed as per post-landing immigration medical surveillance requirements, if applicable.
G. Immigration status at time of arrival in Canada.
H. Country of birth of parents if person is under 20 years of age and Canadian born non-Indigenous.
xii. The Indigenous status of the person.
xiii. Travel history, both within and outside Canada.
xiv. The employment details of the person, including job title and place of employment.
xv. The name and address of the school the person attends, if applicable, including the classroom.
xvi. Contacts.
xvii. Outcome:
A. If the person is deceased, date of death and cause of death.
B. Complications.
C. Absconded — lost to follow-up before treatment completion.
D. Other.
(8) Paragraph 7 of section 5 of the Regulation is revoked and the following substituted:
7. Group B Streptococcal Disease, neonatal, Ophthalmia Neonatorum:
i. The date of the diagnosis.
ii. The name and address of the physician or registered nurse in the extended class attending the person.
iii. The name of the hospital, the date of admission and the date of discharge if the person is admitted to hospital.
iv. Contacts.
v. Medical condition of the person, including signs and symptoms of the infection.
vi. The case classification of the person.
vii. Laboratory findings and other investigative tests, including, without being limited to, culture and antimicrobial sensitivity, serological tests, microscopic examination and cerebrospinal fluid examination, together with the results of the tests.
viii. Initial treatment, if any, of the infection, including, without being limited to, the drugs and dosage used.
ix. Final effective treatment, including, without being limited to, the drugs and dosage used.
x. Risk factors.
xi. The date of death and relation of the infection to the cause of death, if deceased.
(9) Subparagraphs 8 xi and xii of section 5 of the Regulation are revoked and the following substituted:
xi. Risk factors.
xii. Travel history, both within and outside Canada.
(10) Subparagraphs 9 xi, xii and xiii of section 5 of the Regulation are revoked and the following substituted:
xi. Risk factors.
(11) Subparagraphs 9 xvi, xvii, xviii, xix, xx, and xxi of section 5 of the Regulation are revoked and the following substituted:
xvi. Contacts.
(12) Paragraph 10 of section 5 of the Regulation is revoked and the following substituted:
10. Influenza – novel, non-seasonal:
i. The date of diagnosis.
ii. The agent of disease, including subtype.
iii. The name and address of the physician or registered nurse in the extended class attending the person.
iv. Medical condition and status of the person, including signs, symptoms and site, if any, of the infection.
v. The clinical history of the person, including:
A. The name of the hospital, date of admission and the date of discharge from the hospital if the person is admitted to hospital, or the name of the hospital if the person is seen as an out-patient of the hospital.
B. The date and duration of isolation, if isolated.
C. Vaccination history.
vi. The case classification of the person.
vii. Laboratory findings, including, without being limited to, antigen detection, culture and viral strain identification, genetic typing and serological tests.
viii. Association with outbreak and outbreak number, if applicable.
ix. Current treatment, if any, of the infection, setting out the drugs and dosage used and the date treatment commenced and ended.
x. Risk factors.
xi. Travel history, both within and outside Canada.
xii. The employment details of the person, including job title and place of employment.
xiii. The name and address of the school the person attends, if applicable, including the classroom.
xiv. Contacts.
xv. The date of death and relation of the infection to the cause of death, if the person is deceased.
(13) Sub-subparagraph 11 v D of section 5 of the Regulation is revoked.
(14) Subparagraphs 11 xiii and xiv of section 5 of the Regulation are revoked and the following substituted:
xiii. Risk factors.
xiv. Travel history, both within and outside Canada.
(15) Subparagraphs 11 xix, xx, xxi, xxii, xxiii and xxiv of section 5 of the Regulation are revoked and the following substituted:
xix. Contacts.
(16) Subparagraphs 12 viii to xxvii of section 5 of the Regulation are revoked and the following substituted:
viii. The total number of cases in residents and staff that were admitted to hospital, X-ray confirmation of pneumonia, and outbreak-related deaths during the outbreak period.
ix. Laboratory findings (etiologic agent/subtyping).
x. Current treatment, if any, of the residents exhibiting signs and symptoms consistent with the outbreak, setting out the drugs used and the date treatment commenced.
xi. Measures taken to monitor the facility for signs and symptoms consistent with the outbreak in persons who are residents or staff of the institution, including the line list which shall include the name and location of residents and staff within the institution exhibiting signs and symptoms consistent with the description of the outbreak, including clinical details and when the symptoms commenced.
xii. Number of residents and staff in the entire institution and in areas of the institution affected by the outbreak.
xiii. The details of any notification made to any other institution regarding the declaration of an outbreak in the institution for the purposes of preventing the spread of infection.
xiv. Infection control measures utilized to minimize the impact of the outbreak on the residents and staff and to prevent the spread of the infection including, but not limited to, influenza immunization, exclusion of non-immunized persons from the facility, the use of antiviral medications, isolation of ill persons, increased environmental sanitation and restriction of visitors.
(17) Paragraph 13 of section 5 of the Regulation is amended by striking out the portion before subparagraph i and substituting the following:
13. Encephalitis, including primary, viral, post-infectious, vaccine-related, subacute sclerosing panencephalitis, unspecified, and Meningitis, acute:
. . . . .
(18) Subparagraphs 13 xiii, xiv and xv of section 5 of the Regulation are revoked and the following substituted:
xiii. Risk factors.
xiv. Travel history, both within and outside Canada.
(19) Paragraph 14 of section 5 of the Regulation is amended by striking out “Hepatitis D (Delta hepatitis)” in the portion before subparagraph i.
(20) Subparagraph 14 v of section 5 of the Regulation is revoked and the following substituted:
v. History of immunization, including number of doses and date of receipt and post exposure prophylaxis, including the use of Hepatitis B immune globulin, as appropriate.
(21) Subparagraph 14 vii of section 5 of the Regulation is revoked and the following substituted:
vii. Laboratory findings and investigative tests, including, without being limited to, serological tests, together with the results of the tests.
(22) Subparagraph 14 x of section 5 of the Regulation is revoked and the following substituted:
x. Risk factors.
(23) Subparagraph 14 xii of section 5 of the Regulation is revoked and the following substituted:
xii. Travel history, both within and outside Canada.
(24) Subparagraphs 14 xv and xvi of section 5 of the Regulation are revoked and the following substituted:
xv. Contacts.
(25) Paragraph 15 of section 5 of the Regulation is amended by striking out the portion before subparagraph i and substituting the following:
15. Creutzfeldt-Jakob Disease, all types:
. . . . .
(26) Paragraph 16 of section 5 of the Regulation is amended by adding “Paralytic Shellfish Poisoning” after “Lyme Disease” in the portion before subparagraph i.
(27) Subparagraphs 16 x, xi, xii and xiii of section 5 of the Regulation are revoked and the following substituted:
x. Risk factors, including exposure to known reservoirs or vectors, as applicable.
xi. Travel history, both within and outside Canada.
xii. Contacts.
(28) Subparagraph 16 xv of section 5 of the Regulation is revoked.
(29) Subparagraph 17 ix of section 5 of the Regulation is revoked.
(30) Subparagraphs 17 xiii, xiv and xv of section 5 of the Regulation are revoked and the following substituted:
xiii. Risk factors.
xiv. Travel history, both within and outside Canada.
(31) Subparagraphs 17 xviii, xix, xx, xxi, xxii, xxiii and xxiv of section 5 of the Regulation are revoked and the following substituted:
xviii. Contacts.
5. (1) Section 5.2 of the Regulation is amended by striking out the portion before paragraph 1 and substituting the following:
5.2 A report under subsection 27 (1) of the Act in respect of Clostridium difficile infection (CDI) outbreaks in public hospitals shall contain the following information in addition to the information required under subsection 1 (1):
. . . . .
(2) Subparagraph 10 viii of section 5.2 of the Regulation is revoked and the following substituted:
viii. Risk factors.
6. Section 6 of the Regulation is revoked and the following substituted:
6. A medical officer of health who receives a report made under section 25, 26, 27 or 28, subsection 29 (2) or section 30 of the Act shall immediately forward a copy of the report and any other information that the medical officer of health has in respect of the report to the Ministry and to the Ontario Agency for Health Protection and Promotion in a secure manner.
7. (1) Paragraphs 5, 6 and 7 of subsection 7 (1) of the Regulation are revoked and the following substituted:
5. The name and address of the physician or registered nurse in the extended class attending the person, the name and address of the facility where the reportable event was attended to (which may include, but is not limited to, a hospital, clinic, physician’s office or long-term care home), the date seen and the name and address of the person reporting the event.
6. If the person was admitted to hospital as a result of the reportable event, the date of admission and the date of discharge.
7. Signs and symptoms related to the reportable event and, if known, the time, date of onset and duration of each symptom related to the reportable event.
(2) Paragraphs 9 and 10 of subsection 7 (1) of the Regulation are revoked and the following substituted:
9. Laboratory findings, including the dates and results of testing, other investigative procedures and medical consultation relating to the reportable event.
(3) Paragraphs 12 and 13 of subsection 7 (1) of the Regulation are revoked and the following substituted:
12. The name and manufacturer of the vaccine, the date and time on which the vaccine was administered, the dose, site of administration, route, lot number, expiry date and, if the vaccine has been administered as part of a series, ,dose number, of all vaccines received prior to and potentially associated with the reportable event. For the purposes of this paragraph, “potentially associated” does not require a causal relationship between the vaccine and the reportable event.
(4) Subsection 7 (2) of the Regulation is amended by adding “and the Ontario Agency for Health Protection and Promotion” after “Ministry”.
8. Section 8 of the Regulation is amended by adding “and the Ontario Agency for Health Protection and Promotion” after “Ministry” wherever it occurs.
Commencement
9. This Regulation comes into force on the later of January 1, 2018 and the day it is filed.